Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triplex Checkpoint Inhibitors (Ipilimumab, Pembrolizumab, Durvalumab) in Advanced Solid Tumors
NCT05187338Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2021
- Primary completion
- Oct 2029
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, pembrolizumab, durvalumab in solid tumor, sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Nov 2021; status: recruiting.
02
Drugs
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05187338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05187338.